Get the Stockscreener App
8.86
1.56%
-0.14
After Hours:
8.86
Neogenomics Inc stock is traded at $8.86, with a volume of 1.52M.
It is down -1.56% in the last 24 hours and up +10.75% over the past month.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
See More
Previous Close:
$9.00
Open:
$9.01
24h Volume:
1.52M
Relative Volume:
0.73
Market Cap:
$1.15B
Revenue:
$745.97M
Net Income/Loss:
$-99.21M
P/E Ratio:
-11.46
EPS:
-0.7729
Net Cash Flow:
$-5.09M
1W Performance:
-1.77%
1M Performance:
+10.75%
6M Performance:
-15.05%
1Y Performance:
+13.01%
1-Day Range:
$8.735
$9.085
1-Week Range:
$8.18
$10.33
52-Week Range:
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
8.86 | 1.17B | 745.97M | -99.21M | -5.09M | -0.7729 |
TMO
Thermo Fisher Scientific Inc
|
466.76 | 171.91B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.63 | 123.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.97 | 44.73B | 4.30B | 1.06B | 1.04B | 13.08 |
WAT
Waters Corp
|
342.75 | 29.63B | 3.17B | 642.63M | 516.49M | 10.77 |
A
Agilent Technologies Inc
|
117.53 | 31.70B | 7.07B | 1.29B | 993.00M | 4.5355 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-29-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-15-25 | Initiated | Guggenheim | Neutral |
| Apr-30-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-13-25 | Downgrade | The Benchmark Company | Buy → Hold |
| Dec-10-24 | Initiated | Jefferies | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
NeoGenomics shares jump on earnings and analyst upgrades - MSN
NeoGenomics (NEO) CAO exercises RSUs, surrenders shares for taxes - Stock Titan
NeoGenomics (NEO) EVP updates equity awards, reports tax-withholding share move - Stock Titan
NeoGenomics (NEO) COO exercises RSUs, shares withheld for tax - Stock Titan
5 Insightful Analyst Questions From NeoGenomics’s Q1 Earnings Call - The Chronicle-Journal
NeoGenomics slides more than 5% despite fourth-quarter earnings beat - MSN
MSN Money - MSN
Liquidity Mapping Around (NEO) Price Events - Stock Traders Daily
NeoGenomics (NEO) Is Up 13.9% After Strong Q1 Revenue And New Epic Aura Integration - simplywall.st
NeoGenomics (NEO) Q1 2025 Earnings Transcript - AOL.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Opus Genetics (IRD), NeoGenomics (NEO) and Teladoc (TDOC) - The Globe and Mail
A Look At NeoGenomics (NEO) Valuation After Q1 2026 Results And Epic Aura Oncology Integration - Yahoo Finance
BTIG Maintains NeoGenomics(NEO.US) With Hold Rating - Moomoo
Vanguard holds 6.61M NeoGenomics shares (NEO) — 5.09% stake - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
NeoGenomics reports Q1 revenue increase - Gulfshore Business
NeoGenomics Reports First Quarter 2026 Financial Results - HarianBasis.co
Leerink Partners upgrades NeoGenomics (NEO) - MSN
NeoGenomics Earnings Call Highlights NGS-Led Growth - TipRanks
TD Cowen Issues Positive Forecast for NeoGenomics (NASDAQ:NEO) Stock Price - MarketBeat
Vanguard Portfolio Management holds 5.91% of NeoGenomics (NEO) common stock - Stock Titan
Leerink upgrades Neogenomics stock rating on oncology growth outlook By Investing.com - Investing.com Nigeria
NeoGenomics (NASDAQ:NEO) Shares Gap Up Following Analyst Upgrade - MarketBeat
NeoGenomics (NASDAQ:NEO) Upgraded by Leerink Partners to Outperform Rating - MarketBeat
Leerink upgrades NeoGenomics to Outperform, raises target to $25 - TipRanks
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2026 Earnings Call Transcript - Insider Monkey
Leerink Upgrades NeoGenomics to Outperform From Market Perform, Adjusts Price Target to $25 From $12 - marketscreener.com
Needham reiterates Neogenomics stock Buy rating on strong Q1 beat - Investing.com UK
Needham reiterates Neogenomics stock Buy rating on strong Q1 beat By Investing.com - Investing.com India
NeoGenomics Shares Jump on Earnings and Analyst Upgrades - Yahoo Finance
Leerink upgrades Neogenomics stock rating on oncology growth outlook - Investing.com
NeoGenomics upgraded to Buy from Hold at Benchmark - TipRanks
NeoGenomics stock surges following earnings, two upgrades By Investing.com - Investing.com South Africa
NeoGenomics stock surges following earnings, two upgrades - Investing.com
NeoGenomics signals $797M-$803M 2026 revenue outlook following PanTracer Liquid MolDX approval - MSN
Earnings Call Summary | NeoGenomics(NEO.US) Q1 2026 Earnings Conference - Moomoo
NEO Q1 Deep Dive: High-Value Test Expansion and Commercial Execution Drive Oncology Growth - TradingView
Benchmark upgrades NeoGenomics (NEO) - MSN
NeoGenomics Reports First Quarter 2026 Results - BioSpace
NeoGenomics Q1 2026 slides: NGS drives 11% revenue growth By Investing.com - Investing.com Australia
NeoGenomics Q1 2026 Earnings Call Transcript - MarketBeat
NeoGenomics, Inc. Reports Q1 2026 Financial Results and Provides Earnings Highlights - Minichart
NeoGenomics (NASDAQ:NEO) Announces Quarterly Earnings Results, Hits Estimates - MarketBeat
NeoGenomics reports Q1 adjusted EPS 1c, consensus 0c - TipRanks
NeoGenomics (NEO) Q1 2026 Earnings Transcript - The Motley Fool
NeoGenomics Q1 Earnings Call Highlights - MarketBeat
NeoGenomics Q1 2026 slides: NGS drives 11% revenue growth - Investing.com
Earnings call transcript: NeoGenomics Q1 2026 revenue beats forecast By Investing.com - Investing.com Canada
Earnings call transcript: NeoGenomics Q1 2026 revenue beats forecast - Investing.com
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):